Compare · CHPT vs EW
CHPT vs EW
Side-by-side comparison of ChargePoint Holdings Inc. (CHPT) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- CHPT operates in Consumer Discretionary, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $49.43B, about 264.7x CHPT ($186.7M).
- Over the past year, CHPT is down 54.0% and EW is up 12.5% - EW leads by 66.4 points.
- CHPT has been more active in the news (15 items in the past 4 weeks vs 7 for EW).
- Both have 25 recent analyst ratings on file.
- Company
- ChargePoint Holdings Inc.
- Edwards Lifesciences Corporation
- Price
- $7.21-0.35%
- $85.84-0.14%
- Market cap
- $186.7M
- $49.43B
- 1M return
- +17.03%
- +3.72%
- 1Y return
- -53.96%
- +12.46%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- 2019
- News (4w)
- 15
- 7
- Recent ratings
- 25
- 25
ChargePoint Holdings Inc.
ChargePoint Holdings, Inc. provides electric vehicle (EV) charging networks and charging solutions in the United States. It offers a portfolio of hardware, software, and services for commercial, fleet, and residential customers. The company was founded in 2007 and is headquartered in Campbell, California.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest CHPT
- SEC Form 10-Q filed by ChargePoint Holdings Inc.
- ChargePoint Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ChargePoint Reports First Quarter Fiscal Year 2027 Financial Results
- General Counsel Batill Eric was granted 70,000 shares, increasing direct ownership by 89% to 148,610 units (SEC Form 4)
- CFO Khetani Mansi was granted 59,000 shares, increasing direct ownership by 46% to 187,500 units (SEC Form 4)
- CRO Vice John David was granted 54,000 shares, increasing direct ownership by 44% to 175,579 units (SEC Form 4)
- CAO Novruzova Natella Fakhradovna was granted 20,000 shares, increasing direct ownership by 173% to 31,557 units (SEC Form 4)
- CCXO Singh Jagdeep Ca was granted 75,000 shares, increasing direct ownership by 61% to 197,565 units (SEC Form 4)
- ChargePoint Announces Inducement Grants Under NYSE Listed Company Manual Section 303A.08
- ChargePoint and Powers Parts Partner Simplify Fast Charging for Transit Operators
Latest EW
- SEC Form 3 filed by new insider Mistras Theodora
- SVP, Corporate Controller Dahl Andrew M. sold $48,853 worth of shares (568 units at $86.08), decreasing direct ownership by 4% to 15,334 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $2,000,193 worth of shares (23,145 units at $86.42) (SEC Form 4)
- SEC Form SD filed by Edwards Lifesciences Corporation
- CVP, TMTT & Surgical Chopra Daveen sold $126,905 worth of shares (1,500 units at $84.60), decreasing direct ownership by 3% to 44,324 units (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 620 shares at a strike of $72.68 and sold $50,307 worth of shares (620 units at $81.14) as part of a pre-agreed trading plan (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $1,472,678 worth of shares (17,968 units at $81.96), decreasing direct ownership by 30% to 22,798 units (SEC Form 4)
- CEO Zovighian Bernard J converted options into 47,207 shares, covered exercise/tax liability with 26,198 shares, gifted 26,640 shares, received a gift of 26,640 shares and sold $2,833,013 worth of shares (36,351 units at $77.93) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 99,165 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr converted options into 13,457 shares and covered exercise/tax liability with 7,469 shares, increasing direct ownership by 22% to 32,766 units (SEC Form 4)
- CVP, TMTT & Surgical Chopra Daveen converted options into 13,583 shares and covered exercise/tax liability with 7,538 shares, increasing direct ownership by 15% to 45,824 units (SEC Form 4)